NVCT
Nuvectis Pharma, Inc. NASDAQ Listed Feb 4, 2022$18.93
+0.29%
vs $18.88
Mkt Cap $502.3M
52w Low $5.55
56.4% of range
52w High $29.27
50d MA $17.28
200d MA $10.44
P/E (TTM)
—
EV/EBITDA
—
P/B
22.4x
Debt/Equity
0.0x
ROE
-143.6%
P/FCF
-25.7x
RSI (14)
49.00
ATR (14)
$1.47
Beta
-0.21
50d MA
$17.28
200d MA
$10.44
Avg Volume
403.8K
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
1 Bridge Plaza · Fort Lee, NJ 07024 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | BMO | -0.26 | -0.30 | -14.5% | 21.60 | -10.8% | -6.9% | -4.2% | -2.2% | +0.6% | -0.4% | — |
| May 5, 2026 | BMO | -0.30 | -0.26 | +13.3% | 8.89 | -0.1% | +9.2% | +3.0% | +3.2% | +12.9% | -5.1% | — |
| Feb 11, 2026 | BMO | -0.26 | -0.31 | -19.2% | 8.78 | +0.7% | +0.2% | +0.0% | -0.5% | +1.8% | -3.3% | — |
| Nov 4, 2025 | BMO | -0.24 | -0.44 | -83.3% | 5.88 | -0.5% | -3.9% | +0.0% | +0.4% | +8.3% | -1.1% | — |
| Aug 5, 2025 | BMO | -0.25 | -0.30 | -20.0% | 6.90 | -1.4% | -6.4% | +0.0% | -4.5% | -2.8% | +2.2% | — |
| May 6, 2025 | BMO | -0.30 | -0.27 | +10.0% | 8.96 | +0.7% | -2.2% | +0.0% | +5.3% | -2.5% | -6.7% | — |
| Feb 25, 2025 | BMO | -0.28 | -0.36 | -28.6% | 6.93 | +2.9% | -1.0% | +0.0% | -2.2% | -0.3% | -8.2% | — |
| Nov 5, 2024 | BMO | -0.26 | -0.24 | +7.7% | 7.43 | -1.9% | +9.7% | +0.0% | +2.3% | +29.6% | +0.0% | — |
| Aug 6, 2024 | BMO | -0.26 | -0.26 | +0.0% | 6.62 | -0.3% | +0.3% | +0.0% | +3.0% | -0.9% | -7.1% | — |
| May 7, 2024 | BMO | -0.40 | -0.25 | +37.5% | 7.19 | -2.6% | -10.6% | +0.0% | -0.8% | +0.3% | -0.8% | — |
| Mar 5, 2024 | BMO | -0.40 | -0.41 | -2.5% | 10.20 | -0.2% | -3.5% | +0.0% | +3.3% | +1.0% | -1.1% | — |
| Nov 8, 2023 | BMO | -0.38 | -0.37 | +2.6% | 8.24 | +9.2% | -0.1% | +0.0% | -2.1% | +3.6% | +1.0% | — |
| Aug 9, 2023 | BMO | -0.34 | -0.38 | -11.8% | 14.94 | -1.3% | +0.4% | +0.0% | +2.1% | -2.3% | -5.3% | — |
| May 10, 2023 | BMO | -0.44 | -0.27 | +38.6% | 15.13 | +0.1% | +0.8% | +0.0% | +4.8% | +6.2% | -0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.80 | $6.80 | +0.0% | +7.2% | -5.3% | -6.4% | -4.5% | -2.8% |
| Apr 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.33 | $10.30 | -0.3% | -3.6% | -3.4% | -3.8% | +1.3% | -4.4% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.36 | $7.26 | -1.4% | -5.8% | -1.0% | -2.2% | -0.3% | -8.2% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.03 | $7.01 | -0.3% | -5.8% | +0.3% | +3.0% | -0.9% | -7.1% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.19 | $7.00 | -2.6% | -10.6% | -0.8% | +0.3% | -0.8% | +6.6% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.02 | $14.07 | +0.4% | +4.0% | -0.5% | -1.8% | -4.1% | +0.1% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.90 | $11.67 | -1.9% | -4.7% | -2.5% | -9.6% | +7.7% | -7.7% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.82 | $11.82 | +0.0% | +21.6% | -17.5% | -9.7% | -3.3% | -3.5% |
| Jul 13 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $12.69 | $12.69 | +0.0% | -6.5% | -2.8% | -2.1% | +0.4% | -0.3% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.06 | $15.06 | +0.0% | -5.6% | +11.6% | +12.5% | +5.5% | +0.8% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.81 | $7.18 | +5.4% | -2.9% | +11.5% | +2.2% | +3.3% | +3.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | BENTSUR RONDir/Off | Chairman & CEO | Buy | 12,500 | $20.00 | $250K | 3,688,424 | +0.26% | +1.28% |
| Jun 30, 2026 | Mosseri Marlio Charles10% | — | Buy | 50,000 | $18.32 | $916K | 3,186,576 | +0.26% | +1.28% |
8-K · 2.02
!! High
Nuvectis Pharma, Inc. -- 8-K 2.02: Earnings Results
Aug 4
8-K · 8.01
!! High
Nuvectis Pharma, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 23
8-K · 2.02
!! High
Nuvectis Pharma, Inc. -- 8-K 2.02: Earnings Results
Nuvectis Pharma released Q1 2026 financial results and a corporate update, allowing investors to assess the biotech company's operational progress and cash position heading into the second quarter.
May 5
8-K
Nuvectis Pharma, Inc. -- 8-K Filing
Nuvectis Pharma reported 2025 financial results and business highlights, providing investors with updated operational performance and strategic progress through early 2026.
Feb 11
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 659,879 | $5M | New | Mar 2026 |
| 2 | Iridian Asset Management Llc/ct | 651,757 | $5M | Added | Mar 2026 |
| 3 | Northern Trust Corp | 124,212 | $960K | Added | Mar 2026 |
| 4 | Susquehanna International Group, Llp | 105,286 | $814K | Reduced | Mar 2026 |
| 5 | Vanguard Portfolio Management Llc | 92,154 | $712K | New | Mar 2026 |
| 6 | Citadel Advisors Llc | 78,425 | $606K | New | Mar 2026 |
| 7 | Morgan Stanley | 56,022 | $423K | Added | Dec 2025 |
| 8 | Ubs Group Ag | 38,563 | $298K | Added | Mar 2026 |
| 9 | Bank Of New York Mellon Corp | 30,315 | $234K | Reduced | Mar 2026 |
| 10 | Marshall Wace, Llp | 29,223 | $226K | New | Mar 2026 |
| 11 | Cibc Bancorp Usa Inc. | 25,662 | $198K | New | Mar 2026 |
| 12 | Martingale Asset Management L P | 18,024 | $139K | New | Mar 2026 |
| 13 | Nuveen, Llc | 16,749 | $129K | — | Mar 2026 |
| 14 | Bank Of America Corp /de/ | 14,847 | $115K | Added | Mar 2026 |
| 15 | Fmr Llc | 7,568 | $59K | Added | Mar 2026 |
| 16 | Jpmorgan Chase & Co | 6,472 | $48K | Added | Mar 2026 |
| 17 | Wells Fargo & Company/mn | 5,619 | $43K | New | Mar 2026 |
| 18 | Bnp Paribas Financial Markets | 3,542 | $27K | — | Mar 2026 |
| 19 | Barclays Plc | 3,121 | $24K | Reduced | Mar 2026 |
| 20 | Simplex Trading, Llc | 2,596 | $20K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$502.3M
Enterprise Value
$380.2M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.33x
P/B
22.43x
P/S
—
P/FCF
-25.72x
EV/EBITDA
—
Shares Out
21.8M
Financials (TTM)
Revenue
$0
Net Income
-$27.8M
EBITDA
-$28.9M
Free Cash Flow
-$16.0M
Op Cash Flow
-$16.0M
EPS Basic
$-1.32
EPS Diluted
$-1.31
EPS Forward
$-1.27
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$31.7M
Total Liab.
$13.3M
Total Equity
$18.4M
Cash
$31.6M
LT Debt
$0
Book Value/Sh
$0.84
Debt/Equity
0.00x
Current Ratio
2.38
Quick Ratio
2.38
Returns & Growth
ROE
-143.6%
ROA
-83.4%
ROIC
-149.8%
Rev Growth YoY
+0.0%
EPS Growth YoY
-18.9%
Price Returns
2W
-3.4%
1M
+2.9%
3M
+70.7%
6M
+115.0%
12M
+207.9%
Technicals
52W High
$29.27
52W Low
$5.55
50d MA
$17.28
200d MA
$10.44
RSI (14)
49.00
ATR (14)
$1.47
Beta
-0.21
Avg Volume
404K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$10.00
High
$10.00
Low
$10.00
Median
$10.00
Data updated apr 26, 2026 4:14pm
· Source: financialmodelingprep.com